SCOTTSDALE, Ariz., June 14, 2007 (PRIME NEWSWIRE) -- TASER International, Inc. (Nasdaq:TASR) a market leader in advanced electronic control devices today announced it will introduce its much-anticipated XREP wireless 12-gauge Neuro Muscular Incapacitation (NMI) projectile at the annual TASER(r) Tactical Conference on July 9, 2007 in Chicago, Illinois. The Conference, normally restricted to active duty law enforcement and military officers, will include an open session for media to attend the keynote address by Tom and Rick Smith, Chairman and CEO respectively, at the conference's opening from 9:00 to 10:30 a.m.
"The Wireless eXtended Range Electronic Projectile (XREP) is truly a revolutionary technology breakthrough, culminating five years of intensive research and development and a dream that began 14 years ago with the founding of TASER International," said Rick Smith, CEO. "The XREP introduces not only amazingly miniaturized TASER technology, but groundbreaking flight stabilization and microprocessor-controlled intelligent electrode selection technologies - in a package that weighs only 14 grams, or half an ounce. The XREP projectile is, by an order of magnitude, the most sophisticated weapon system ever launched from a 12-gauge shotgun platform."
XREP product images, video demonstrations, and public specifications will not be released until the keynote presentation. Limited previews of advanced features will be posted on TASER International's website at www.TASER.com/XREP - with the keynote address and full product features being released on July 9.
The Company plans to release the XREP into a field test for 6 to 12 months starting in the fall of 2007, with full release of production in 2008 upon completion of the field trial phase. Law enforcement, military, and press can sign up to attend the TASER Tactical Conference (Media may attend the keynote XREP demonstration only) at www.TASER.com/XREP.
About TASER International, Inc.
TASER International provides advanced electronic control devices for use in the law enforcement, military, private security and personal defense markets. TASER(r) devices use proprietary technology to incapacitate dangerous, combative or high-risk subjects who pose a risk to law enforcement officers, innocent citizens or themselves in a manner that is generally recognized as a safer alternative to other uses of force. TASER technology saves lives every day, and the use of TASER devices dramatically reduces injury rates for police officers and suspects. For more information on TASER life-saving technology, please call TASER International at (800) 978-2737 or visit our website at www.TASER.com.
The TASER International logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2931
Note to Investors
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements, without limitation, regarding our expectations, beliefs, intentions or strategies regarding the future. We intend that such forward-looking statements be subject to the safe-harbor provided by the Private Securities Litigation Reform Act of 1995. The forward-looking information is based upon current information and expectations regarding TASER International. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results could materially differ from what is expressed, implied, or forecasted in such forward-looking statements.
TASER International assumes no obligation to update the information contained in this press release. These statements are qualified by important factors that could cause our actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to: (1) market acceptance of our products; (2) our ability to establish and expand direct and indirect distribution channels; (3) our ability to attract and retain the endorsement of key opinion-leaders in the law enforcement community; (4) the level of product technology and price competition for our products; (5) the degree and rate of growth of the markets in which we compete and the accompanying demand for our products; (6) risks associated with rapid technological change and new product introductions; (7) competition; (8) litigation including lawsuits resulting from alleged product related injuries and death; (9) media publicity concerning allegations of deaths and injuries occurring after use of the TASER device and the negative effect this publicity could have on our sales; (10) TASER device tests and reports; (11) product quality; (12) implementation of manufacturing automation; (13) potential fluctuations in our quarterly operating results; (14) financial and budgetary constraints of prospects and customers; (15) order delays; (16) dependence upon sole and limited source suppliers; (17) negative reports concerning the TASER device; (18) fluctuations in component pricing; (19) government regulations and inquiries; (20) dependence upon key employees and our ability to retain employees; (21) execution and implementation risks of new technology; (22) ramping manufacturing production to meet demand; (23) medical and safety studies; (24) field test results; and (25) other factors detailed in our filings with the Securities and Exchange Commission, including, without limitation, those factors detailed in the Company's Annual Report on Form 10-K and its Form 10-Qs.
The statements made herein are independent statements of TASER International. The inclusion of any third parties does not represent an endorsement of any TASER International products or services by any such third parties.